Atara Biotherapeutics (NASDAQ:ATRA) CEO Anhco Nguyen Sells 2,915 Shares

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Anhco Nguyen sold 2,915 shares of Atara Biotherapeutics stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $13.19, for a total transaction of $38,448.85. Following the completion of the transaction, the chief executive officer directly owned 64,974 shares in the company, valued at $857,007.06. This represents a 4.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Atara Biotherapeutics Trading Up 4.3%

ATRA stock traded up $0.59 on Thursday, hitting $14.33. 3,714 shares of the company’s stock traded hands, compared to its average volume of 96,030. The stock has a market cap of $103.28 million, a price-to-earnings ratio of 6.57 and a beta of 0.26. Atara Biotherapeutics, Inc. has a 1-year low of $5.01 and a 1-year high of $18.70. The stock has a fifty day moving average of $13.74 and a 200-day moving average of $11.07.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.51. The company had revenue of $3.45 million during the quarter, compared to the consensus estimate of $2.74 million. Atara Biotherapeutics had a negative return on equity of 41.78% and a net margin of 15.40%. On average, equities research analysts anticipate that Atara Biotherapeutics, Inc. will post -10.39 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Atara Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Raymond James Financial Inc. acquired a new stake in Atara Biotherapeutics during the second quarter valued at approximately $31,000. GSA Capital Partners LLP raised its position in Atara Biotherapeutics by 33.8% in the 3rd quarter. GSA Capital Partners LLP now owns 26,213 shares of the biotechnology company’s stock worth $376,000 after purchasing an additional 6,622 shares during the last quarter. Marshall Wace LLP acquired a new stake in Atara Biotherapeutics in the second quarter worth about $327,000. Geode Capital Management LLC lifted its stake in shares of Atara Biotherapeutics by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 60,136 shares of the biotechnology company’s stock valued at $464,000 after purchasing an additional 1,457 shares during the period. Finally, Mackenzie Financial Corp raised its holdings in Atara Biotherapeutics by 183.5% in the third quarter. Mackenzie Financial Corp now owns 63,816 shares of the biotechnology company’s stock worth $914,000 after purchasing an additional 41,302 shares during the period. 70.90% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of Atara Biotherapeutics in a research report on Thursday, November 13th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.